Bioanalytical Testing Services Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Bioanalytical Testing Services Market Report is Segmented by Molecule Type (Small Molecules, Large Molecules), Test Type (Bioavailability & Bioequivalence, Pharmacokinetics, and More), End User (Pharmaceutical Companies, Biopharmaceutical & Biotech Firms, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Bioanalytical Testing Services Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Bioanalytical Testing Services Market with other markets in Healthcare Industry

Bioanalytical Testing Services Market Analysis by Mordor Intelligence

The Bioanalytical Testing Services Market size is estimated at USD 4.29 billion in 2025, and is expected to reach USD 6.65 billion by 2030, at a CAGR of 9.19% during the forecast period (2025-2030).

The acceleration reflects the sector’s transition from a support function to a strategic driver of precision-medicine programs, regulatory filings, and faster drug-development cycles. Outsourcing now underpins more than 50% of clinical study analytics as sponsors trim fixed laboratories and lean on specialist contract research organizations (CROs) for high-throughput capacity. Biologics, biosimilars, and complex modalities demand high-resolution instrumentation that few sponsors keep in-house, prompting multiyear service contracts for ligand-binding assays, high-resolution mass spectrometry, and immunogenicity testing. Meanwhile, the global push toward harmonized guidelines such as ICH M10 is encouraging a uniform validation approach that reduces repeat testing while simultaneously raising the technical bar for laboratories. Supply-chain disruptions during the COVID-19 pandemic further reinforced outsourcing decisions and hastened adoption of automated platforms that cut assay turn-around times.

Key Report Takeaways

  • By molecule type, small molecules retained 64.27% of the bioanalytical testing services market share in 2024, while large molecules are forecast to post an 11.55% CAGR through 2030. 
  • By test type, bioavailability and bioequivalence held 36.54% revenue share in 2024; biomarker assays are projected to expand at a 12.87% CAGR to 2030. 
  • By end user, pharmaceutical companies commanded 56.32% share of the bioanalytical testing services market size in 2024, whereas CDMOs are on course for a 13.56% CAGR between 2025-2030. 
  • By geography, North America led with 42.44% revenue share in 2024; Asia-Pacific is set to grow at 12.19% CAGR through 2030.

Segment Analysis

By Molecule Type: Large Molecules Drive Innovation

Large molecules generated rapid momentum, even though small molecules still held 64.27% of the bioanalytical testing services market share in 2024. The large-molecule segment is expanding at an 11.55% CAGR due to monoclonal antibodies, fusion proteins, and peptide therapeutics that necessitate ligand-binding assays, cell-based potency tests, and immunogenicity evaluations. This demand compels laboratories to install high-throughput Gyrolab immunoassay platforms and multi-attribute-method mass-spectrometry workflows that identify structural variants within minutes.

Investment intensity continues to rise. WuXi AppTec, for example, lifted peptide-manufacturing capacity to 32,000 L of solid-phase synthesis reactors, underpinning a surge in comparative analytical requests from biosimilar developers. Sponsors favor analytical similarity packages over long efficacy studies, pushing advanced orthogonal techniques into routine service. As the pipeline diversifies, the bioanalytical testing services market will rely heavily on cross-disciplinary skillsets spanning biochemistry, statistics, and automation to match rising complexity.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Test Type: Biomarker Assays Lead Innovation

Bioavailability and bioequivalence work accounted for 36.54% revenue in 2024, safeguarding regulatory compliance for generics. Yet, biomarker assays headline growth with a 12.87% CAGR, mirroring precision-medicine strategies that appear in more than 40% of recent FDA approvals. Sponsors increasingly request multi-omics panels that combine proteomics, metabolomics, and lipidomics to stratify patients, a capability pioneered by firms such as Dalton Bioanalytics through single-run assays that lower cost and boost data depth.

AI-powered analytics shorten turnaround windows, allowing near real-time dose adjustments in adaptive trials. Immunogenicity and neutralizing-antibody assays also display robust demand as biologics volumes climb, requiring ultralow detection limits and confirmatory workflows. ADME studies remain fundamental, but high-resolution platforms increase metabolite mapping efficiency, anchoring their relevance within the broader service mix of the bioanalytical testing services industry.

By End User: CDMOs Accelerate Partnership Models

Pharmaceutical companies controlled 56.32% of 2024 revenue, yet contract development and manufacturing organizations are on track for a 13.56% CAGR as integrated research-to-manufacture partnerships gain traction. BioDuro’s CRDMO model illustrates the appeal: unified discovery, analytical, and GMP manufacturing reduce tech-transfer risks and compress timelines. CDMOs are scaling bioanalytical labs to support biologics pipelines and, in turn, capturing multi-year master service agreements.

WuXi Biologics reported non-COVID service revenue growth, evidencing the stickiness of integrated engagements. Academic and public research institutes remain steady but slower growth users, focused on translational research rather than commercial submissions. Overall, the bioanalytical testing services market size tied to CDMOs will widen as sponsors consolidate vendors for end-to-end accountability.

Bioanalytical Testing Services Market: Market Share by End User
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America generated 42.44% of global revenue in 2024, underpinned by concentrated pharmaceutical headquarters, FDA proximity, and extensive GLP infrastructure. Major providers such as Labcorp deploy more than 14,000 employees across domestic labs that underpin top-selling drug programs. Yet, talent shortages and elevated labor costs pressure margins and drive selective outsourcing to lower-cost regions. Canadian facilities complement US capacity with bilingual submissions, while Mexico’s near-shoring momentum is prompting fresh investment in GLP sites aligned with US import rules.

Europe ranks second due to cohesive EMA frameworks and leadership in biosimilars. Germany, France, and the United Kingdom host clusters of CRO and CDMO facilities that collaborate with academic hubs, and Eurofins Scientific alone runs over 900 European laboratories performing 450 million tests annually. Post-Brexit, the UK fast-tracked biosimilar pathways to sustain competitiveness, demonstrating a flexible regulatory posture that continues to attract biopharma analytical work. EU investments in biopharmaceutical manufacturing hubs and Horizon Europe R&D grants will keep demand buoyant.

Asia-Pacific represents the fastest-growing zone at 12.19% CAGR, driven by clinical-trial migration, expanding manufacturing capacity, and supportive government incentives. China leads sample volumes as local CROs scale capacity, while Japan’s status as the third-largest pharmaceutical market ensures a steady flow of complex submissions requiring bilingual documentation. South Korea and Taiwan leverage tax credits and expedited reviews, luring multinationals searching for efficient enrollment and cost controls. India’s national push for GLP compliance and Australia’s biotechnology cluster diversify regional capabilities. As a result, the bioanalytical testing services market will see APAC revenue converge with Western levels during the second half of the decade.

Bioanalytical Testing Services Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The market shows moderate fragmentation yet increasing consolidation as scale and technology investments differentiate leaders. High-resolution mass-spectrometry systems above USD 500,000, coupled with expert staffing, create substantial entry barriers. Eurofins Scientific exemplifies scale leverage, offering more than 200,000 validated assays across 61 countries and completing 450 million tests per year. Acquisition activity centers on complementary biophysical platforms; Bruker’s purchase of Sierra Sensors and Waters’s takeover of Wyatt Technology extend service breadth for complex biotherapeutics.

Strategic direction favors vertical integration and regional expansion. Providers are linking discovery screening to regulated bioanalysis and commercial QC under one contract to eliminate tech-transfer friction. Robotics-driven dark labs promise 24-hour workflows that mitigate scientist shortages and lower error rates. White-space remains in multi-omics and AI-assisted data-mining niches where early movers such as Dalton Bioanalytics operate. Overall, competition hinges on marrying regulatory fluency, global logistics, and automated analytics to support sponsors navigating a more intricate therapeutic landscape.

Bioanalytical Testing Services Industry Leaders

  1. SGS SA

  2. Syneos Health

  3. Charles River Laboratories

  4. Labcorp Drug Development (Covance)

  5. ICON plc

  6. *Disclaimer: Major Players sorted in no particular order
Bioanalytical Testing Services Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • April 2025: Thermo Fisher Scientific reported first quarter 2025 revenue of USD 10.36 billion with 15% growth, launching innovative products including the Thermo Scientific Vulcan Automated Lab for semiconductor analysis and Olink Reveal proteomics kits for precision medicine applications. The company also entered a Technology Alliance Agreement with the Chan Zuckerberg Institute for Advanced Biological Imaging.
  • March 2025: Labcorp announced the acquisition of select assets from BioReference Health's innovative oncology and related clinical testing services businesses, aimed at enhancing access to high-quality laboratory services and expanding Labcorp's portfolio in cancer care. The transaction is expected to generate significant annual revenue and close in the second half of 2025.
  • February 2025: Charles River Laboratories announced a strategic agreement with Singapore General Hospital to provide CGMP-compliant master cell banking and next-generation sequencing testing services for cord blood-derived allogeneic CAR-T cells. The NGS services enhance viral contamination detection in cell banks, offering reliable testing options that meet regulatory requirements while supporting novel cancer therapeutic development.
  • January 2025: Charles River Laboratories expanded its Apollo™ ecosystem with the launch of Apollo for CRADL, a cloud-based platform designed to enhance vivarium rental services and streamline drug discovery processes across nearly 30 facilities globally. This strategic initiative integrates various services including safety assessments and biologics testing, providing real-time data access and administrative task management to accelerate research timelines.

Table of Contents for Bioanalytical Testing Services Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Outsourcing of Analytical Testing
    • 4.2.2 Expansion of Biologics & Biosimilars Pipeline
    • 4.2.3 Growing Global Clinical-Trial Volumes
    • 4.2.4 Stringent PK/PD & BE Regulatory Mandates
    • 4.2.5 Adoption of Microsampling & DBS in Decentralized Trials
    • 4.2.6 AI-Driven Analytics Cutting Assay Turnaround Time
  • 4.3 Market Restraints
    • 4.3.1 Complex & Rapidly-Evolving Global Regulations
    • 4.3.2 Shortage of Skilled Bioanalytical Scientists
    • 4.3.3 High Capex for HR-Mass-Spectrometry Platforms
    • 4.3.4 Sample-Integrity Risks in At-Home Collections
  • 4.4 Porter’s Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitutes
    • 4.4.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value in USD)

  • 5.1 By Molecule Type
    • 5.1.1 Small Molecules
    • 5.1.2 Large Molecules
  • 5.2 By Test Type
    • 5.2.1 Bioavailability & Bioequivalence
    • 5.2.2 Pharmacokinetics
    • 5.2.3 Pharmacodynamics
    • 5.2.4 Absorption-Distribution-Metabolism-Excretion
    • 5.2.5 Immunogenicity & Neutralizing-Antibody Assays
    • 5.2.6 Biomarker & Omics-Based Assays
    • 5.2.7 Other Tests
  • 5.3 By End User
    • 5.3.1 Pharmaceutical Companies
    • 5.3.2 Biopharmaceutical & Biotech Firms
    • 5.3.3 Contract Development & Manufacturing Organizations
    • 5.3.4 Academic & Government Institutes
  • 5.4 By Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Labcorp Drug Development (Covance)
    • 6.3.2 Charles River Laboratories
    • 6.3.3 Thermo Fisher – PPD
    • 6.3.4 Eurofins Scientific
    • 6.3.5 ICON plc
    • 6.3.6 Syneos Health
    • 6.3.7 SGS SA
    • 6.3.8 Intertek Group plc
    • 6.3.9 WuXi AppTec
    • 6.3.10 Medpace Holdings
    • 6.3.11 BioAgilytix Labs
    • 6.3.12 Frontage Labs
    • 6.3.13 Toxikon Corp.
    • 6.3.14 Covance-Monogram
    • 6.3.15 Altasciences
    • 6.3.16 SGS Vitrology
    • 6.3.17 Eurofin-Advinus
    • 6.3.18 Analytical Bio-Clear

7. Market Opportunities & Future Outlook

  • 7.1 White-Space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Bioanalytical Testing Services Market Report Scope

Bioanalysis involves quantitative measurement of xenobiotics, like small molecule drugs and their metabolites and biological molecules. Bioanalytical testing services are used in the development and validation of robust bioanalytical methods in body fluids and tissue specimens. These tests are used to support pre-clinical and Phase I through Phase IV clinical trials.

The bioanalytical testing services market is segmented by molecule type (small molecule and large molecule), by test type (bioavailability and bioequivalence studies, pharmacokinetics, pharmacodynamics, and other test types), and by geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Molecule Type Small Molecules
Large Molecules
By Test Type Bioavailability & Bioequivalence
Pharmacokinetics
Pharmacodynamics
Absorption-Distribution-Metabolism-Excretion
Immunogenicity & Neutralizing-Antibody Assays
Biomarker & Omics-Based Assays
Other Tests
By End User Pharmaceutical Companies
Biopharmaceutical & Biotech Firms
Contract Development & Manufacturing Organizations
Academic & Government Institutes
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
By Molecule Type
Small Molecules
Large Molecules
By Test Type
Bioavailability & Bioequivalence
Pharmacokinetics
Pharmacodynamics
Absorption-Distribution-Metabolism-Excretion
Immunogenicity & Neutralizing-Antibody Assays
Biomarker & Omics-Based Assays
Other Tests
By End User
Pharmaceutical Companies
Biopharmaceutical & Biotech Firms
Contract Development & Manufacturing Organizations
Academic & Government Institutes
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the bioanalytical testing services market?

The market generated USD 4.29 billion in 2025 and is projected to reach USD 6.65 billion by 2030.

Which geographic region is growing the fastest?

Asia-Pacific leads with a forecast 12.19% CAGR, driven by clinical-trial migration and regulatory reforms.

Why are biomarker assays expanding so rapidly?

Precision-medicine strategies require multi-omics profiling, pushing biomarker assay demand at a 12.87% CAGR through 2030.

How are CDMOs influencing the market?

CDMOs integrate discovery to manufacturing, enabling 13.56% CAGR growth by offering single-contract accountability.

What are the main regulatory challenges?

Divergent global validation standards and tighter data-integrity rules raise compliance costs and prolong project timelines.

How is automation addressing workforce shortages?

Robotics-driven “dark labs” and AI analytics deliver 24-hour throughput, reducing reliance on scarce specialist scientists.

Page last updated on: July 3, 2025

Bioanalytical Testing Services Market Report Snapshots